Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
NCT02616393
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Leptomeningeal Metastases
Brain Metastases
Interventions
DRUG:
Tesevatinib
Sponsor
Kadmon Corporation, LLC